Gilead Sciences agreed to acquire Ouro Medicines in a deal that pays roughly $1.675 billion upfront and up to $500 million in milestones, adding OM336 (gamgertamig), a BCMAxCD3 T‑cell engager, to its inflammation and cell‑therapy portfolio. Gilead said early trials show rapid, deep B‑cell depletion and granted Fast Track and Orphan designations from the FDA. The company expects registrational studies to start in 2027 and is in talks for Galapagos to absorb Ouro’s operating assets and staff, with Galapagos to lead development and Gilead retaining worldwide commercialization rights outside China. T‑cell engagers (TCEs) recruit T cells to target disease‑causing cells; regulatory designations accelerate development and can change commercialization timelines.